Relapsed AML in a Patient Presenting to a College Health Center: A Case Report
Summary
Primary care providers are vital for monitoring adolescent and young adult cancer survivors. Early recognition of relapsed leukemia in college students by primary care providers is crucial for timely treatment.
Area of Science:
- Oncology
- Adolescent and Young Adult (AYA) Medicine
- Primary Care
Background:
- Acute myelogenous leukemia (AML) is a significant cancer in the adolescent and young adult (AYA) population.
- Cure rates for AYAs with AML remain lower than in younger patients, despite improved survival.
- Primary care providers (PCPs) are essential for managing AYA cancer survivors, particularly in monitoring for relapse and late effects.
Purpose of the Study:
- To highlight the importance of PCPs in recognizing relapsed leukemia in college students.
- To emphasize the unique needs of AYA cancer survivors within the college health setting.
- To underscore the role of PCPs in early detection and referral for relapsed cancers.
Main Methods:
- Case study presentation of a college student with symptoms of relapsed leukemia.
- Discussion of the PCP's role in the college health center.
- Emphasis on differential diagnosis for AYA cancer survivors presenting with new complaints.
Main Results:
- The case illustrates how a PCP can encounter and diagnose relapsed leukemia in a college student.
- Highlights the potential for delayed diagnosis if PCPs are not attuned to AYA survivor needs.
- Underscores the necessity for PCPs to consider cancer relapse in their differential diagnoses for this population.
Conclusions:
- PCPs must be vigilant in monitoring AYA cancer survivors for signs of relapse.
- Early recognition and prompt referral by college health providers can significantly impact outcomes for AYAs with relapsed leukemia.
- Tailored care and awareness of specific AYA survivor needs are critical for effective primary care.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.2K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
